ArticleThe international journal of cardiovascular imaging2026
Myocardial late gadolinium enhancement is strongly associated with ventricular arrhythmias in mitral valve prolapse.
Article in The international journal of cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis of patients with mitral valve prolapse (MVP) largely depends on the presence of ventricular arrhythmias. This study aims to identify association between Cardiac MRI (CMR) based findings with ventricular arrhythmias in MVP patients. Consecutive patients (n = 45, mean age 56 ± 17 y) with MVP underwent CMR scans. Premature ventricular beats (PVC) and ventricular tachycardia (VT) were recorded by 24-hour Holter monitoring and exercise stress testing. Myocardial late gadolinium enhancement (M -LGE) was calculated as percentage of left ventricular (LV) mass and was analyzed by tertiles - 1st tertile (0%), 2nd (1-4%) and 3rd tertile ≥ 5% of the LV mass. Mitral annular disjunction (MAD) was measured in millimeters in a 3-chamber steady state free precession (SSFP) sequence. Papillary muscle fibrosis (PM - LGE) presence was recorded using the LGE sequence. The combined clinical endpoint (CEP) was defined as the presence of VT, multiple (> 10%) or multiform PVC, ablation due to ventricular arrhythmia and implantable cardioverter defibrillator insertion. M-LGE > 0% in 27 patients (64%) was recorded. The CEP was documented in 47%, 46% and 93% of the 1st, 2nd and 3rd M - LGE% tertiles, respectively (p value = 0.014). A multivariable logistic regression analysis assessing associations with CEP, including LV ejection fraction, PM-LGE, and M-LGE%, was performed. M - LGE% remains strongly associated with CEP as a continuous variable, as well as in the 3rd tertile: OR 1.43; 95%CI 1.05-1.94, p = 0.02 and OR 13.41 95%CI 1.49-120.67, p = 0.02, respectively. Myocardial fibrosis detected by CMR - LGE, particularly when ≥ 5% of LV mass was strongly associated with arrhythmic risk in MVP. CMR - based fibrosis quantification should be considered in routine evaluation to improve risk stratification.
Indexed as
Identifiers
42754746What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.